Antiviral drugs for the neonate--the risk-benefit ledger.
D000225:Adenine / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001089:Arabinose / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D001927:Brain Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004279:DNA, Viral / Q000096:biosynthesis; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy*; D051379:Mice; D009705:Nucleosides / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious
D000998:Antiviral Agents; D004279:DNA, Viral; D009705:Nucleosides; D003561:Cytarabine; D001089:Arabinose; D000225:Adenine; D007065:Idoxuridine